When was FibroGen founded?

FibroGen was founded in 1993 and raised its 1st funding round 9 years after it was founded.

Where is FibroGen located?

FibroGen is headquartered in San Francisco, United States.

How many employees does FibroGen have?

As of May 31, 2026, the latest employee count at FibroGen is 270.

Is FibroGen a funded company?

FibroGen is a funded company, having raised a total of $215M across 8 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Aug 19, 2002.

When was the latest funding round of FibroGen?

FibroGen's latest funding was a $***** Post IPO round on Dec 08, 2014, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $3.79B in funding in 2026 to date.

What is the annual revenue of FibroGen?

Annual revenue of FibroGen is between $10M and $50M as on Dec 31, 2024

Where does FibroGen rank among its competitors?

FibroGen ranks 176th amongst 3324 active competitors, of which 1122 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of FibroGen?

FibroGen's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

FibroGen - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

FibroGen has built upon its research experience in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to generate clinical programs targeting multiple therapeutic areas. Its most advanced product candidate, FG-4592, is an oral small-molecule inhibitor of HIF prolyl hydroxylases for the treatment of anemia in chronic kidney disease (CKD). Its second product candidate, FG-3019, is a monoclonal antibody (mAb) for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and liver fibrosis.

Key Metrics

Founded Year

1993

Location

San Francisco, United States

Stage

Public

Total Funding

$215M in 8 rounds

Latest Funding Round

Post IPO, Dec 08, 2014, $*****

Investors

Adage Capital Management & 27 more

Ranked

176^th among 3324 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

270 as on May 31, 2026

Similar Companies

BeiGene & 644 more

Exit Details

Public

View FibroGen's full profile

FibroGen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Fibrogen Inc CIN: 921299 , United States, Active	Sep 28, 1993	$10M - $50M (As on Dec 31, 2024)	592 (As on Jan 31, 2023)	-

FibroGen got listed on Nov 14, 2014.

Click here to take a look at FibroGen's IPO in detail

FibroGen has raised a total funding of $215M over 8 rounds. Its first funding round was on Aug 19, 2002. FibroGen has 28 institutional investors.

Here is the list of recent funding rounds of FibroGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 08, 2014	9674966	Post IPO	1537283	7817740	4135645	3072089
Apr 18, 2007	2262913	Series D	2563086	4212404	9770087	5533397
Jan 19, 2007	5803501	Series D	3540890	9744401	2046764	9338817

Access funding benchmarks and valuations. Sign up today!

View details of FibroGen's funding rounds and investors

The founders of FibroGen is Thomas Neff.

Here are the details of FibroGen's key team members:

Thomas Neff: Chairman, Founder and CEO of FibroGen.

View details of FibroGen's Founder profiles and Board Members

FibroGen's employee count trend

FibroGen has 270 employees as of May 26. Here is FibroGen's employee count trend over the years:

Uncover FibroGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of FibroGen include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of FibroGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
176th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	HighGear Ventures, T. Rowe Price & 26 others	60/100